Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENEPID deucravacitinib in inflammatory epidermal genodermatoses
2022-502879-32-00Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deucravacitinib in epidermolysis bullosa simplex (EBS) and congenital ichthyosis, sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Primary efficacy of deucravacitinib. Started Sep 2023; status: completed.
02
Drugs
deucravacitinib
03
Conditions
epidermolysis bullosa simplex (EBS)congenital ichthyosis
Beyond the preview
Go deeper on 2022-502879-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502879-32-00.